5‐ASA vs placebo
Serious adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.06 [0.44, 2.59]3 studies · 577 participantsLow